Intellectual Property

The project has outlined a clear three-pronged IP strategy covering diagnostic tools, antibody design, and vaccine development. However, no patents have been filed yet — all IP filings are listed as 'planned' with unknown timelines. The early results (gingipain biomarker signatures, Peptide 1007 protective antibody data) could strengthen IP filings, and the unpublished Path 2 data represents potentially patentable discoveries. However, the competitive landscape includes established players (Cambridge/Oxford, UCL, Biogen, Alchemab, Araclon Biotech) working in overlapping spaces. The pathogen hypothesis for AD is well-known in the literature, which may limit novelty claims. The lack of any formalized patent applications at this stage, despite having preliminary data that could support filings, is a notable gap.

Utility Of Candidates

The project is primarily at the biomarker discovery stage rather than therapeutic candidate development. No specific drug candidates or therapeutic molecules have been characterized. Peptide 1007 shows promise as a protective antibody target in elderly non-demented individuals, but its therapeutic viability has not been tested — in vivo validation in AD mouse models is acknowledged as a needed but unfunded next step. The gingipain biomarker finding is more diagnostic than therapeutic, though it could enable patient stratification for existing drugs. The proposed vaccine and antibody therapeutics remain conceptual without defined candidates, formulations, or preliminary efficacy data. The diagnostic tool concept (saliva-based testing) is more tangible but still lacks a defined product. For TRL 2, some candidate emergence is expected, and the project shows early signals but lacks concrete therapeutic candidates.

Prospects For Safety

At this early TRL 2 stage, no direct safety data exists for any therapeutic candidate since none have been developed yet. However, several factors are relevant: (1) The saliva/blood-based diagnostic approach is inherently low-risk and less invasive than current AD diagnostics (PET scans). (2) The competitive landscape notes that Araclon Biotech's ABvac40 active vaccine was terminated at Phase II due to safety concerns, highlighting real safety risks in the AD vaccine space. (3) The biomarker-driven patient stratification approach could actually improve safety by targeting therapies to biologically appropriate patient subsets. (4) No early toxicity signals have been identified, but this is largely because no therapeutic intervention has been tested. (5) The vaccine approach carries inherent immunological risks that remain uncharacterized. The score reflects a neutral position — no red flags but also no safety de-risking data, with the caveat that the diagnostic pathway has an inherently favorable safety profile.